Jaypirca
Q2 2026 revenue $192M; EC approved monotherapy for CLL across all lines.
The numbers
Revenue$192MQ2 2026 · source ↗
What it is
Pirtobrutinib, a BTK inhibitor for chronic lymphocytic leukemia and other B-cell cancers.
Why it matters to the stock. Jaypirca's uptake against established BTK inhibitors is a useful signal for Lilly's oncology growth outside the metabolic franchise.
News
FDA approves Jaypirca as first-line treatment for untreated CLL/SLL
The FDA approved Jaypirca (pirtobrutinib) on October 2, 2026 as a first-line treatment for adults with previously untreated CLL or SLL who do not have a 17p deletion.
Product
EU regulator backs Jaypirca for CLL across all treatment lines
The EU's medicines committee gave a positive opinion for Jaypirca (pirtobrutinib) in adults with chronic lymphocytic leukaemia across all lines of therapy, including patients who have not had a BTK inhibitor.
Regulation